O uso do tamoxifeno no tratamento adjuvante do câncer de mama estrogênio - positivo / Ajduvant treatment of estrogen receptor positive breast cancer with tamoxifen

Authors

  • Walter Mori Junior
  • Maria Clara Tertuliano
  • Emanuel Fernandes de Souza Xavier
  • Rebecca Perin Sarmento
  • Gabriel de Oliveira Pereira
  • Samarone de Freitas Júnior
  • Pedro Henrique Pereira da Silva
  • Geovanna Botta Oliveira
  • Ana Carolina Ambrósio Rodrigues
  • Thiago Soares dos Santos

DOI:

https://doi.org/10.34119/bjhrv5n4-095

Keywords:

câncer de mama, tamoxifeno, terapia hormonal, terapia adjuvante.

Abstract

O câncer de mama é a principal causa de morte por razões oncológicas entre a população feminina e alguns subtipos da doença tem relação direta com o hormônio estrogênio. Por isso, nas últimas décadas, foram desenvolvidos medicamentos que agem diretamente nessa via hormonal da mulher com o diagnóstico de câncer de mama estrogênio positivo. O principal representante dessa classe de medicamento é o tamoxifeno, agente antiestrogênico que atua diretamente nos receptores desse hormônio na mama. O objetivo desse estudo foi analisar de maneira extensa o uso do tamoxifeno no tratamento do câncer de mama estrogênio-positivo. Após uma extensa busca de artigos, foram selecionados inicialmente 36, dentre os quais 21 se adequaram aos critérios estabelecidos para fazerem parte da revisão.  O uso do tamoxifeno se mostrou benéfica como terapia hormonal adjuvante do câncer de mama estrogênio-positivo, impactando positivamente o prognóstico da doença em relação às taxas de recidiva e mortalidade. Sua adoção no tratamento tem um excelente custo benefício, concluindo que os benefícios superam os malefícios.

References

Akram, M., Iqbal, M., Daniyal, M., Khan, A. U. (2017). Awareness and current knowledge of breast cancer. Biological Research, 50(33).

Beatson, G. (1896). ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES. The Lancet, 148(3803), 162–165.

Bogush, T. A., Polezhaev, B. B., Mamichev, I. A., Bogush, E. A., Polotsky, B. E., Tjulandin, S. A., Ryabov, A. B. (2018). Tamoxifen never ceases to amaze: new finding on non-estrogen receptor molecular targets and mediated effects. Cancer Investigation, 36(4), 211-220.

BREAST INTERNATIONAL GROUP (BIG) COLLABORATIVE GROUP. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine, 353(26), 2747-2757.

Budny, A., Staroslawska, E., Budny, B., Wojcik, R., Hys, M., Kozlowski, P., … Burdan, F. (2019). Epidemiology and diagnosis of breast cancer. Polish Medical Journal, 46(275), 195-204.

Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., … Peto, R. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet, 381(9869), 805–816.

DeCensi, A., Puntoni, M., Guerrieri-Gonzaga, A., Caviglia, S., Avino, F., Cortesi, L., ... Bonanni, B. (2019). Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. Journal of Clinical Oncology, 37(19), 1629-1637.

Draganescu, M., Carmocan, C. (2017). Hormone Therapy in Breast Cancer. Chirurgia (Bucur)., 112(4), 413-417.

Dunn, B. K., Ford, L. G. (2001). From Adjuvant theraphy to breast cancer prevention: BCPT and STAR. Breast Journal, 7(3), 144-157.

EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. (1998). Tamoxifen for early breast cancer: an overview of the randomised trials. The Lancet, 351(9114), 1451-1467.

EARLY BREAST CANCER TRIALISTS’ COLLABORATIVE GROUP (EBCTCG). (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet, 378(9793), 771–784.

EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet, 386(10001), 1341-1352.

Fisher, B., Constantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., … Fisher, E. R. (1989). A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor–positive tumors. New England Journal of Medicine, 320(8), 479-484.

Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Lang, I., … Regan, M. M. (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 379(2), 122–137.

Goss, P. E., Ingle, J. N., Pritchard, K . I., Robert, N. J., Muss, H., Gralow, J., … Parulekar, W. R. (2016). Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine, 375(3), 209–219.

Jebahi, F., Sharma, S., Bloss, J. E., Wright, H. H. (2021). Effects of tamoxifen on cognition and language in women with breast cancer: A systematic and a scoping review. Phychooncology, 30(8), 1262-1277.

Jordan, V. C., Gapstur, S., Morrow, M. (2001). Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst, 93(19), 1449-1457.

Lee, W., Cheng, M., Chao, H., Wang, P. (2008). The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. Taiwan Journal of Obstet. Gynecol., 47(1), 24-31.

Mathew, A., Davidson, N. E. (2015). Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Breast, 24, 120–125.

Novick, A. M., Scott, A. T., Epperson, C. N., Schneck, C. D. (2020). Neuropsychiatric effects of tamoxifen: Challenges and opportunities. Frontiers in Neuroendocrinology, 59.

Shagufta. Ahmad, I. (2018). Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives. European Journal of Medicinal Chemistry, 143, 515-531.

Published

2022-07-22

Issue

Section

Original Papers